Equities Analysts Issue Forecasts for QUIT FY2026 Earnings

Achieve Life Sciences, Inc. (NASDAQ:QUIT) – Investment analysts at HC Wainwright dropped their FY2026 earnings estimates for shares of Achieve Life Sciences in a report released on Wednesday, November 11th. HC Wainwright analyst B. Folkes now expects that the company will earn ($1.38) per share for the year, down from their prior forecast of ($1.02). The consensus estimate for Achieve Life Sciences’ current full-year earnings is ($0.92) per share. HC Wainwright also issued estimates for Achieve Life Sciences’ Q4 2026 earnings at ($0.25) EPS, FY2027 earnings at ($0.67) EPS and FY2028 earnings at $0.28 EPS.

Other equities analysts also recently issued reports about the stock. Weiss Ratings initiated coverage on shares of Achieve Life Sciences in a research note on Wednesday. They issued a “sell (d-)” rating on the stock. Zacks Research started coverage on Achieve Life Sciences in a research report on Tuesday. They set a “hold” rating for the company. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Achieve Life Sciences presently has a consensus rating of “Reduce”.

Achieve Life Sciences Stock Performance

Shares of NASDAQ:QUIT opened at $6.29 on Friday. The company has a debt-to-equity ratio of 0.03, a current ratio of 10.49 and a quick ratio of 0.95. Achieve Life Sciences has a 12-month low of $2.62 and a 12-month high of $8.64.

Achieve Life Sciences Company Profile

Achieve Life Sciences is a clinical-stage biopharmaceutical company focused on developing treatments for nicotine dependence. Its lead product candidate, cytisinicline, is being studied as a potential aid for people seeking to stop smoking or using other nicotine products. Cytisinicline is a plant-derived compound that acts on nicotine receptors in the brain. The company is conducting clinical development with the goal of obtaining regulatory approval; the candidate is not an approved treatment.